Chemosensitivity/Resistance Assay Included As Part of the NCCN Principles of Chemotherapy

Pittsburgh, PA ( PressReleaseCollection ) February 26, 2010 – Precision Therapeutics announced today that The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section. While the NCCN Guidelines™ state that this technology is not intended to supplant standard of care chemotherapy, chemosensitivity/resistance assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. This is a NCCN category 3 recommendation.<br /><br />Recent studies presented at ASCO and published in the International Journal of Gynecologic Cancer, evaluated the association between prediction of response to chemotherapy and progression-free interval and overall survival in ovarian cancer.<br /><br />“We offer our gratitude to NCCN on behalf of the many ovarian cancer patients who could be faced with the potential side effects of ineffective chemotherapies. Not only are oncologists recognizing the benefits of using chemosensitivity and resistance assays when faced with equivalent therapeutic options, but they are also paving the way for greater support of personalized medicine in oncology,” says Karen Kaplan, CEO of the Ovarian Cancer National Alliance. <br /><br />Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country’s fifth most common cause of cancer mortality in women. In the year 2009, there were more than 21,000 new diagnoses and nearly 15,000 deaths from this neoplasm in the United States.<br /><br />The NCCN Clinical Practice Guidelines in Oncology™ are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines™ are available free of charge at NCCN.org. <br /><br />About the Ovarian Cancer National Alliance <br />The Ovarian Cancer National Alliance is the foremost advocate for women with ovarian cancer in the United States. To advance the interests of women with ovarian cancer, the organization advocates at a national level for increases in research funding for the development of an early detection test, improved health care practices, and life-saving treatment protocols. The Ovarian Cancer National Alliance educates health care professionals and raises public awareness of the signs and symptoms of ovarian cancer. For more information, visit <a href="http://www.ovariancancer.org">www.ovariancancer.org</a>.<br /><br />About Precision Therapeutics<br />Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.<br /><br />Precision’s ChemoFx®, a proprietary drug response marker, measures an individual patient’s tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician’s experience and provide valuable patient-specific information, particularly when there is non-uniform response to standard cancer treatment or no clear choice for the next regimen.<br /><br />For more information:<br /><a href="http://www.precisiontherapeutics.com">http://www.precisiontherapeutics.com</a><br /><a href="http://www.chemofx.com">http://www.chemofx.com</a><br /><br />Media Contact:<br />Pam Ranallo<br />Precision Therapeutics Inc.<br />412-432-1500 ext. 1502<br />pranallo@ptilabs.com<br /><br />###

Chemosensitivity/Resistance Assay Included As Part of the NCCN Principles of Chemotherapy

Pittsburgh, PA ( PressReleaseCollection ) February 26, 2010 – Precision Therapeutics announced today that The National Comprehensive Cancer ...

Read more »

PRECISION THERAPEUTICS TO PRESENT AT JEFFRIES 2010 GLOBAL HEALTHCARE SERVICES CONFERENCE

PITTSBURGH, PA ( PressReleaseCollection ) January 26, 2010 – Precision Therapeutics, Inc. today announced that CEO Sean McDonald plans to provide a company presentation to the Jeffries 2010 Global Healthcare Services Conference at the Mandarin Oriental Hotel in New York City on Monday, January 25, 2010. The presentation may include a discussion of the company’s marketed products, strategy for growth, pipeline, financial results and expectations, and other matters relating to the personalized medicine industry.<br /><br />Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions in cancer therapy.<br /><br />Precision’s ChemoFx®, a proprietary drug response marker, measures an individual patient’s tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician’s experience and provide valuable patient-specific information, particularly when there is non-uniform response to standard <a href="http://www.chemofx.com">cancer treatment</a> or no clear choice for the next regimen.<br /><br />For more information:<br /><a href="http://www.precisiontherapeutics.com">http://www.precisiontherapeutics.com</a><br /><a href="http://www.chemofx.com">http://www.chemofx.com</a><br /><br /><br />###

PRECISION THERAPEUTICS TO PRESENT AT JEFFRIES 2010 GLOBAL HEALTHCARE SERVICES CONFERENCE

PITTSBURGH, PA ( PressReleaseCollection ) January 26, 2010 – Precision Therapeutics, Inc. today announced that CEO Sean McDonald plans to pr...

Read more »

PRECISION THERAPEUTICS CEO PRESENTS AT J.P. MORGAN 28TH ANNUAL HEALTHCARE CONFERENCE

PITTSBURGH, PA ( PressReleaseCollection ) January 25, 2010 – Precision Therapeutics, Inc. today announced that CEO Sean McDonald provided a company presentation at the J.P. Morgan 28th Annual Healthcare Conference, held at the Westin St. Francis Hotel in San Francisco, California, on Thursday, January 14, 2010. The presentation included a discussion of the company’s marketed products, its strategy for growth, and other matters relating to its business.<br /><br />Precision Therapeutics, headquartered in Pittsburgh, Pennsylvania, is a life science company and leader in the development of innovative technology that delivers personalized diagnostics to physicians with the goal of supporting and optimizing <a href="http://www.chemofx.com/targeted-chemotherapy/cancer-treatment.html">difficult cancer therapy decisions</a>.<br /><br />Precision’s ChemFx®, a proprietary drug response marker, measures an individual patient’s tumor response to various chemotherapeutic and biological agents prior to treating the patient. ChemoFx® can complement the physician’s experience and provide valuable patient-specific information, as there is typically not a uniform response to standard cancer treatment or no clear choice for the next regimen.<br /><br />For more information:<br /><a href="http://www.precisiontherapeutics.com">http://www.precisiontherapeutics.com</a><br /><a href="http://www.chemofx.com">http://www.chemofx.com</a><br /><br /><br />###

PRECISION THERAPEUTICS CEO PRESENTS AT J.P. MORGAN 28TH ANNUAL HEALTHCARE CONFERENCE

PITTSBURGH, PA ( PressReleaseCollection ) January 25, 2010 – Precision Therapeutics, Inc. today announced that CEO Sean McDonald provided a ...

Read more »

Many Important November Developments for Precision Therapeutics

Pittsburgh, PA ( Pressreleasecollection ) December 23, 2009 – Precision Therapeutics was recognized by Inc. Magazine as the 64th fastest growing privately owned healthcare company in the US and placed within the top 83 percentile of all private U.S. companies with a three year growth rate of 351percent. The Inc. 500/5000 is an annual ranking that recognizes the significant accomplishments of the fastest-growing privately held entrepreneurial companies in America, whose unsurpassed innovation, creativity and performance have redefined their industry.<br /><br />“We are very excited and honored to be ranked 64 of 100 in the health category of the Inc. 500,” said McDonald. “Our success and subsequent ranking on this list reflects the passion of Precision Therapeutics employees and the commitment Pittsburgh has made to supporting local businesses in the region.”<br /><br />Precision Therapeutics and the other Inc. 5000 companies are responsible for creating more than 1 million jobs since their founding; making the list perhaps the best example of the impact that private, fast-growing companies can have on the economy.<br /><br />For a complete copy of the press release, please visit our ChemoFx® website at: http://www.chemofx.com/chemotherapy-news/chemotherapy-news.html<br /><br />New Website Feature on www.ChemoFx.com<br /><br />As part of Precision Therapeutics’ continuing efforts to make ChemoFx® and <a href="http://www.chemofx.com">personalized chemotherapy</a> available to more patients in need, we are adding a “Find a Doctor” function on our website that will allow patients to search for physicians in their area who use the ChemoFx® Drug Response Marker. If you would like to be included in our “Find a Doctor” function and have not received a letter or e-mail, please contact Becky Yacht at: byacht@ptilabs.com, or speak with your Clinical Oncology Specialist (COS) for more information.<br /><br />ChemoFx Reference Guide<br /><br />For physicians wanting more information about ChemoFx®, we will soon offer a CD kit that includes our full list of publications, a sample final report, patient billing information and much more. If you are interested in receiving this kit, contact your local COS and one will be sent to you hot off the CD burner!<br /><br />Precision Therapeutics to Open Third Facility<br /><br />Precision has committed to leasing additional laboratory space in Pittsburgh’s Lawrenceville neighborhood. Approximately 80 employees will work from this new location, which is expected to be occupied by summer 2010.<br /><br />Precision Launches into Lung<br /><br />Lung cancer panels for both the primary and recurrent setting will be added to our list of standard drug panels this November. These lists of available agents will include Pemetrexed, making us the first and only drug response marker or assay to offer sensitivity and resistance testing for the popular lung cancer drug. Our standard panel for renal cancer will also be updated with the addition of sunitinib. These are important steps as we continue exploring and verifying the effectiveness of ChemoFx® as a diagnostic tool for various tumor types.<br /><br />New Publication in Anticancer Research: Assessment of Erlotinib in Chemoresponse Assay*<br /><br />A new article on the ability of ChemoFx® to successfully test for patient response to erlotinib was recently published in Anticancer Research. In this study, three different non-small-cell lung cancer cell lines and 34 primary human lung tumor specimens were tested for chemoresponse to the drug. The relative responsiveness of the specimens was found to be consistent with previously published patterns of response, with 8.8% of cultures scored as “responsive” by the DRM, compared to the 8.9% objective clinical response rate reported in published literature. This serves as validation of our ability to successfully test for patient response to erlotinib with the ChemoFx® Drug Response Marker.<br /><br />*Shara D Rice, Bush. J.A., Brower, S.L. Assessment of Erlotinib in Chemoresponse Assay. Anticancer Research (2009) 29:1993-1198<br /><br />What we do<br /><br />Precision Therapeutics is a CLIA-certified diagnostics services company dedicated to providing physicians and patients with actionable clinical information to <a href="http://www.chemofx.com/cancer-treatment/why-chemotherapy.html">personalize cancer treatments</a>. Precision’s ChemoFx®, a proprietary live tumor cell-based platform, measures an individual patient’s tumor sensitivity and resistance to a range of therapeutic alternatives under consideration by a physician. This may help guide physicians when evaluating each patient’s <a href="http://www.chemofx.com/cancer-treatment/why-chemotherapy.html">cancer treatment options</a>.<br /><br />###

Many Important November Developments for Precision Therapeutics

Pittsburgh, PA ( Pressreleasecollection ) December 23, 2009 – Precision Therapeutics was recognized by Inc. Magazine as the 64th fastest gro...

Read more »